Amgen: Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint

Date : 09/13/2019 @ 2:51PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 132.84  0.0 (0.00%) @ 2:03PM

Amgen: Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint

Historical Stock Chart

2 Months : From Aug 2019 to Oct 2019

Click Here for more Amgen Charts.

By Colin Kellaher


Amgen Inc. (AMGN) on Friday said a phase 3 study evaluating its cancer drug Kyprolis in combination with dexamethasone and Johnson & Johnson's (JNJ) Darzalex compared with Kyprolis and dexamethasone alone met its primary endpoint of progression-free survival.

The Thousand Oaks, Calif., biotechnology company said the regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.

Amgen said the phase 3 study confirms the benefit for patients shown in an earlier phase 1 study using the same combination, adding that it plans to discuss the data with health authorities in preparation for regulatory submissions.


Write to Colin Kellaher at


(END) Dow Jones Newswires

September 13, 2019 09:36 ET (13:36 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.